Cagrilinitide – 20mg

Cagrilintide: long-acting amylase analogue studied in diabetes and weight research.

Cagrilintide is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. CagriSema is combined with Cagrilintide and Semaglutide. The clinical phase II trial of CagriSema in diabetic patients was successfully completed with superior weight loss and glucose-lowering effects compared to simethicone. The trial included 92 patients with type 2 diabetes with overweight, randomized equally into 3 groups: CagriSema injection (2.4 mg of simeplutide and 2.4 mg of cagrilintide), 2.4 mg of simeplutide alone, and 2.4 mg of cagrilintide alone. the treatment duration was 32 weeks, and subjects had a mean baseline HbA1c was 8.4% and mean baseline weight was 106 kg. The results showed that in terms of weight loss, CagriSema injection significantly outperformed simepaglutide (5.1%) and cagrilintide (8.1%) by 15.6% of body weight loss.

Product intended for research purposes

Additional informations:

• The product (substance) isn’t a food or diet supplement and is not suitable for human consumption.
• Keep out of children’s reach
• Keep container tightly closed.
• Store in a dry, cool and shaded place; protect from moisture.
• Store only in the original container.
• Avoid contact during pregnancy and breast feeding.
• Consult a doctor in the event of feeling unwell or having adverse effects related to the contact with the substance.